EUVIMEDEUVIMED entdecken
Fallbericht

Osimertinib in a patient with end-stage kidney disease not on hemodialysis

Marta Pirovano iD, Andrea Luciani, Giulia Vanessa Re Sartò, Annalisa Bramati, Laura Cosmai

Journal of Nephrology · 2024

DOI: 10.1007/s40620-024-02014-6 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Nephrology, 2024. Verfasst von Marta Pirovano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Onconephrology Outpatient Clinic, Division of Nephrology and Dialysis, UOC Nephrology and Dialysis, ASST Fatebenefratelli Sacco, Fatebenefratelli Hos…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Kidney Failure, Chronic, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective in non- small cell lung cancer (NSCLC) with EGFR mutations. Since the drug is primally eliminated by the fecal route no dose adjustment is needed in patient with chronic-kidney disease (CKD); despite this there is limited data about its safety in cancer patients with end-stage renal disease (ESRD). Herein, we reported a case report of a 77-year-old woman, diagnosed in 2018 with lung adenocarcinoma EGFR mutated with lymph nodal and cerebral metastasis, who started Osimertinib 80 mg/day. She under- went 41 cycles of therapy with no Osimertinib interruptions, no severe toxicities and obtaining complete radiological response. We conclude that Osimertinib has an acceptable safety profile also in cancer patients with ESRD not undergoing hemodialysis (HD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsKidney Failure, ChronicLung NeoplasmsAdenocarcinoma of LungProtein Kinase InhibitorsAntineoplastic AgentsBrain NeoplasmsHumansAgedFemaleErbB ReceptorsTreatment OutcomeMutationRenal DialysisLymphatic MetastasisIndolesPyrimidines

Stichwörter der Autor:innen

Epidermal Growth Factor ReceptorHemodialysisNon-small cell lung cancerOsimertinib

Substanzen

osimertinibAcrylamidesAniline CompoundsProtein Kinase InhibitorsErbB ReceptorsEGFR protein, humanAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Onconephrology Outpatient Clinic, Division of Nephrology and Dialysis, UOC Nephrology and Dialysis, ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, Piazzale Principessa Clotilde, 3, 20121, Milan, Italy. marta.pi…
  • UOC Medical Oncology, Ospedale Di Legnano, ASST Ovest Milanese, Legnano, Italy.
  • Onconephrology Outpatient Clinic, Division of Nephrology and Dialysis, UOC Nephrology and Dialysis, ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, Piazzale Principessa Clotilde, 3, 20121, Milan, Italy.
  • UOC Medical Oncology, Ospedale Fatebenefratelli E Oftalmico, ASST Fatebenefratelli-Sacco, Milan, Italy.

ORCID-Profile: Marta Pirovano

Zitieren

APA

Pirovano, M., Luciani, A., Re Sartò, G. V., Bramati, A., & Cosmai, L. (2024). Osimertinib in a patient with end-stage kidney disease not on hemodialysis. Journal of Nephrology. https://doi.org/10.1007/s40620-024-02014-6

Vancouver

Pirovano M, Luciani A, Re Sartò GV, Bramati A, Cosmai L. Osimertinib in a patient with end-stage kidney disease not on hemodialysis. Journal of Nephrology. 2024. doi:10.1007/s40620-024-02014-6

BibTeX
@article{Pirovano2024,
  author = {Pirovano, Marta and Luciani, Andrea and Re Sartò, Giulia Vanessa and Bramati, Annalisa and Cosmai, Laura},
  title = {Osimertinib in a patient with end-stage kidney disease not on hemodialysis},
  journal = {Journal of Nephrology},
  year = {2024},
  doi = {10.1007/s40620-024-02014-6}
}
Kostenlos starten →